STOK Stoke Therapeutics, Inc.

22.80-1.30 (-5.39%)
Close: November 21, 2019

23.290.49 (+2.15%)
After hours

Quote

Previous Close
$22.80
Day Range
$22.60-$24.11
52 Week Range
$19.21-$39.04
Volume
91,720
Avg Volume
119,637
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$746.24M
Enterprise Value (EV)
$683.39M
PE Ratio
-
EV/EBITDA
-54.38
Price/Sales
-
Price/Book
7.10
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-$214.00K
EBITDA
-$12.57M
EPS, ttm
-
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
2/26/2020 (96 days)
Debt to Equity
-
Debt
$42.55M
Cash
$105.40M
Net Debt
-

Performance

Beta
0.51
200 Day Moving Avg
$26.71
50 Day Moving Avg
$24.36
52 Week Change
-5.75%
YTD Change
-11.14%
1 Month Change
6.07%
3 Month Change
-24.50%
6 Month Change
-5.75%
1 Year Change
-5.75%
2 Year Change
-5.75%
5 Year Change
-5.75%

Share Count

Shares Outstanding
32.7M
Float
15.5M
Restricted Shares
17.2M
Restricted Shares, %
52.60%

Stoke Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Edward M. Kaye

Website: http://www.stoketherapeutics.com

Description: Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Employees: -